Literature DB >> 24366653

Time intervals from aneurysmal subarachnoid hemorrhage to treatment and factors contributing to delay.

Menno Robbert1, Menno R Germans, Jantien Hoogmoed, H A Stéphanie van Straaten, Bert A Coert, W Peter Vandertop, Dagmar Verbaan.   

Abstract

In the management of aneurysmal subarachnoid hemorrhage (aSAH), aneurysm treatment as early as feasible is mandatory to minimize the risk of a rebleed and may thus improve outcome. We assessed the different time intervals from the first symptoms of aSAH to start of aneurysm treatment in an effort to identify which factors contribute mostly to a delay in time to treatment. In 278 aSAH patients, time intervals between the different steps from initial hemorrhage to aneurysm treatment were retrospectively reviewed, and delaying factors were determined. Half of the patients presented to a hospital within 115 min (IQR 60-431). The median (IQR) interval from hemorrhage to diagnosis was 169 min (96-513), and from diagnosis to treatment 1,057 min (416-1,428), or 17.6 h. Aneurysm treatment started within 24 h in 76 % of treated patients. Independent factors predicting delay to treatment were primary presentation at a referring hospital and admission to the treatment center later in the day. Delay in treatment was not independently related to poor outcome. The interval to aneurysm treatment might be improved upon by immediate and direct transport to the treatment center combined with optimization of in-hospital logistics, following the 'time-is-brain' concept so successfully adopted in the treatment of ischemic stroke.

Entities:  

Mesh:

Year:  2013        PMID: 24366653     DOI: 10.1007/s00415-013-7218-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

1.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

2.  Identifying stroke in the field. Prospective validation of the Los Angeles prehospital stroke screen (LAPSS).

Authors:  C S Kidwell; S Starkman; M Eckstein; K Weems; J L Saver
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

3.  Considerable delay in diagnosis and acute management of subarachnoid haemorrhage.

Authors:  Carl Christian Larsen; Vagn Eskesen; John Hauerberg; Charlotte Olesen; Bertil Romner; Jens Astrup
Journal:  Dan Med Bull       Date:  2010-04

Review 4.  Timing of surgery for aneurysmal subarachnoid haemorrhage.

Authors:  P C Whitfield; P J Kirkpatrick
Journal:  Cochrane Database Syst Rev       Date:  2001

5.  Ultra-early (within 24 hours) aneurysm treatment after subarachnoid hemorrhage.

Authors:  George Kwok Chu Wong; Ronald Boet; Stephanie Chi Ping Ng; Matthew Chan; Tony Gin; Benny Zee; Wai Sang Poon
Journal:  World Neurosurg       Date:  2011-11-01       Impact factor: 2.104

Review 6.  Time trends in outcome of subarachnoid hemorrhage: Population-based study and systematic review.

Authors:  C E Lovelock; G J E Rinkel; P M Rothwell
Journal:  Neurology       Date:  2010-04-07       Impact factor: 9.910

7.  Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association.

Authors:  E Sander Connolly; Alejandro A Rabinstein; J Ricardo Carhuapoma; Colin P Derdeyn; Jacques Dion; Randall T Higashida; Brian L Hoh; Catherine J Kirkness; Andrew M Naidech; Christopher S Ogilvy; Aman B Patel; B Gregory Thompson; Paul Vespa
Journal:  Stroke       Date:  2012-05-03       Impact factor: 7.914

8.  Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment.

Authors:  P J Lindsberg; O Häppölä; M Kallela; L Valanne; M Kuisma; M Kaste
Journal:  Neurology       Date:  2006-07-25       Impact factor: 9.910

Review 9.  European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage.

Authors:  Thorsten Steiner; Seppo Juvela; Andreas Unterberg; Carla Jung; Michael Forsting; Gabriel Rinkel
Journal:  Cerebrovasc Dis       Date:  2013-02-07       Impact factor: 2.762

10.  International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomized trial.

Authors:  Andrew Molyneux; Richard Kerr; Irene Stratton; Peter Sandercock; Mike Clarke; Julia Shrimpton; Rury Holman
Journal:  J Stroke Cerebrovasc Dis       Date:  2002 Nov-Dec       Impact factor: 2.136

View more
  5 in total

Review 1.  Spontaneous Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis Describing the Diagnostic Accuracy of History, Physical Examination, Imaging, and Lumbar Puncture With an Exploration of Test Thresholds.

Authors:  Christopher R Carpenter; Adnan M Hussain; Michael J Ward; Gregory J Zipfel; Susan Fowler; Jesse M Pines; Marco L A Sivilotti
Journal:  Acad Emerg Med       Date:  2016-09-06       Impact factor: 3.451

2.  Short-term tranexamic acid treatment reduces in-hospital mortality in aneurysmal sub-arachnoid hemorrhage: A multicenter comparison study.

Authors:  R Post; M R Germans; H D Boogaarts; B Ferreira Dias Xavier; R Van den Berg; B A Coert; W P Vandertop; D Verbaan
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

3.  Update of the ULtra-early TRranexamic Acid after Subarachnoid Hemorrhage (ULTRA) trial: statistical analysis plan.

Authors:  René Post; Menno R Germans; Bert A Coert; Gabriël J E Rinkel; W Peter Vandertop; Dagmar Verbaan
Journal:  Trials       Date:  2020-02-18       Impact factor: 2.279

4.  Timelines and rebleeds in patients admitted into neurosurgical care for aneurysmal subarachnoid haemorrhage.

Authors:  Angelika Sorteberg; Luis Romundstad; Wilhelm Sorteberg
Journal:  Acta Neurochir (Wien)       Date:  2021-01-06       Impact factor: 2.216

5.  A Multicenter prospective study of poor-grade aneurysmal subarachnoid hemorrhage (AMPAS): observational registry study.

Authors:  Bing Zhao; Xianxi Tan; Hua Yang; Kuang Zheng; Zequn Li; Ye Xiong; Ming Zhong
Journal:  BMC Neurol       Date:  2014-04-17       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.